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Background: The transcription factor (TF) forkhead box P3 (FOXP3) is constitutively expressed at high levels in
naturally occurring CD4+CD25+ regulatory T cells (nTregs). It is not only the most accepted marker for that cell
population but is also considered lineage determinative. Chromatin immunoprecipitation (ChIP) of TFs in
combination with genomic tiling microarray analysis (ChIP-on-chip) has been shown to be an appropriate tool for
identifying FOXP3 transcription factor binding sites (TFBSs) on a genome-wide scale. In combination with
microarray expression analysis, the ChIP-on-chip technique allows identification of direct FOXP3 target genes.
Results: ChIP-on-chip analysis of the human FOXP3 expressed in resting and PMA/ionomycin–stimulated Jurkat T
cells revealed several thousand putative FOXP3 binding sites and demonstrated the importance of intronic regions
for FOXP3 binding. The analysis of expression data showed that the stimulation-dependent down-regulation of
IL-22 was correlated with direct FOXP3 binding in the IL-22 promoter region. This association was confirmed by
real-time PCR analysis of ChIP-DNA. The corresponding ChIP-region also contained a matching FOXP3 consensus
sequence.
Conclusions: Knowledge of the general distribution patterns of FOXP3 TFBSs in the human genome under resting
and activated conditions will contribute to a better understanding of this TF and its influence on direct target
genes, as well as its importance for the phenotype and function of Tregs. Moreover, FOXP3-dependent repression
of Th17-related IL-22 may be relevant to an understanding of the phenomenon of Treg/Th17 cell plasticity.
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To prevent inflammation-related collateral tissue damage
and immune pathology caused by an excessive immune
response to autoimmune-related self-antigens or pathogen-
associated antigens, the immune system has developed a di-
verse spectrum of mechanisms allowing efficient regulation
and suppression of innate and adaptive immune responses
that maintain a homeostatic environment. One important
cellular component mediating the control of immune
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reproduction in any medium, provided the orvarious subpopulations. The so-called naturally occurring
Treg cells (nTregs) have been described as being CD4+
T cells expressing high levels of the interleukin-2 receptor
alpha-chain (known as CD25) and exhibiting immune-
suppressive capability to self- and non-self-antigens [1].
The nTregs develop in the thymus along with conventional
T cells and are considered to be the primary component for
the establishment and maintenance of peripheral immuno-
logical self-tolerance [2]. Later it has been found that
nTregs in mice can be identified by the expression of the
transcription factor (TF) forkhead box P3 (Foxp3) [3].
Mutations in the human FOXP3 gene are linked to the
Immunodysregulation polyendocrinopathy enteropathy
X-linked syndrome (IPEX), which is accompanied by a
defect in the development of nTregs. This defect affects
the peripheral tolerance and surveillance of auto-reactive
T cells, thereby promoting systemic autoimmunity [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forkhead-binding protein domain (FKH) [5], which med-
iates the general interaction of FOXP3 with genomic
DNA [6] and with FOXP3 transcription factor binding
sites (TFBSs) in particular. TFBSs can be defined by con-
sensus sequences that have been determined for FOXP3
in several studies. De novo identification of human
FOXP3 consensus sequences revealed the sequence 50-
GTAAACAA-30 [7]. Furthermore, in vitro optimization
studies demonstrated that the sequence 50-GTAAACA-30
is preferred for FOXP3 binding to DNA [8].
The human FOXP3 gene consists of 11 exons encod-
ing for various splice variants. Besides the full-length
431 aa variant, three truncated transcript variants lack-
ing exon 2 (FOXP3Δ2), exon 7 (FOXP3Δ7), or both
(FOXP3Δ2,Δ7) have been described [9, 10]. However, the
full-length and the Δ2 variant are the main isoforms and
are equally expressed in resting human nTreg cells [10].
Generally, all isoforms share the same protein domain
entities: an N-terminal repressor domain, a C2H2 zinc-
finger domain, a leucine zipper domain and a C-
terminal FKH domain, which also contains a nuclear
localization signal. Although all known FOXP3 isoforms
share the FKH domain, it is important to note that
FOXP3 can also act as a co-regulator independent of the
FKH binding domain [11, 12].
Currently, the only contribution of FOXP3 to a full
nTreg phenotype that can be defined either by gene
expression patterns or on a functional level exhibiting
the whole bandwidth of nTreg suppressive mechanisms
is under constant controversial discussion, especially in
the human system [13–15]. Nevertheless, because of
their immune modulatory capability Tregs are consid-
ered key candidates for therapeutic interventions
aimed at treating a broad variety of immunological
diseases. If we are to better define the role of FOXP3
within nTregs, we must first gain knowledge about its
condition-dependent global binding behavior, about its
functional TFBSs throughout the genome, and about
its competence in regulating the expression of adjacent
genes.
Here we present the results of chromatin immu-
noprecipitation in combination with genomic tiling
microarray (ChIP-on-chip) analysis of FOXP3Δ2, one of
the main human FOXP3 isoforms, ectopically ex-
pressed in a Jurkat T-cell line under resting and
mitogen-stimulated conditions. The main focus of the
study was to investigate direct FOXP3/DNA inter-
action mediated by means of the FKH having direct
impact on adjacent gene loci. The analyses revealed
global distribution characteristics of human FOXP3
TFBSs and identified the cytokine IL-22 as a previ-
ously unknown direct transcriptional target of FOXP3
in activated T cells.Results
Ectopically expressed FOXP3 suppresses IL-2 production
in human T cells
To study FOXP3 TFBSs by ChIP-on-chip analysis,
we generated a human T-cell line stably expressing
FOXP3Δ2. Jurkat T cells were retrovirally transfected
with either a viral construct expressing FOXP3Δ2 and
green fluorescent protein (GFP) as a reporter (hereafter
termed J-FOXP3) or an empty viral construct expressing
only GFP (hereafter termed J-GFP). Transfected GFPhigh
T cells were sorted and subsequently expanded in vitro.
FOXP3 over-expression was confirmed by quantitative
real-time reverse transcriptase polymerase chain reaction
(RT-PCR), flow cytometry, and Western blot analysis, as
shown in Figure 1. FOXP3 mRNA levels were nearly 7
times higher in J-FOXP3 T cells than in J-GFP control
cells or wild-type Jurkat T cells. Western blot analysis
and intracellular FOXP3 staining also confirmed FOXP3
over-expression on the protein level exclusively in J-
FOXP3 T cells.
Because interleukin-2 (IL-2) is one of the best-studied
direct target genes of FOXP3, with confirmed FOXP3
binding sites in the IL-2 promoter [16], we confirmed
the functionality of ectopically expressed FOXP3 protein
by evaluating its influence on IL-2 production. We
determined IL-2 expression by using real-time RT-PCR
(Figure 2A) and intracellular cytokine staining followed
by fluorescence-activated cell sorting (FACS) analysis in
untreated and phorbol 12-myristate 13-acetate (PMA)/
ionomycin–stimulated Jurkat T cells (Figure 2B). As
expected, J-FOXP3 T cells produced less IL-2 on both
the transcriptional level and the protein level than did
control or wild-type cells, a finding demonstrating the
ability of ectopically expressed FOXP3 to suppress IL-2
production. Taken together, the generated J-FOXP3 T
cell line produced a functional FOXP3 protein and thus
met an important requirement for the subsequent ChIP-
on-chip studies.
Mapping of genomic FOXP3 binding regions
It has been previously demonstrated that FOXP3 bind-
ing capability is sensitive to cellular Ca2+ influx and that
it can be dramatically increased in T cells upon stimula-
tion with PMA and ionomycin [16]. Therefore, we ana-
lyzed FOXP3 TFBSs in both resting and PMA/
ionomycin–activated J-FOXP3 T cells in two independ-
ent replicate experiments involving a FOXP3-specific
ChIP procedure, as described in Materials and Methods.
Our experiments identified 3343 ChIP regions in rest-
ing J-FOXP3 T cells and 3632 ChIP regions in stimu-
lated J-FOXP3 T cells. More than 50% of these ChIP
regions were smaller than 125 bp; this size provided a
sufficient mapping resolution for the ChIP regions
(data not shown). The number of ChIP regions per
Figure 1 Confirmation of FOXP3 expression in transfected Jurkat T cells. (A) Quantitative real-time RT-PCR for FOXP3 expression. Bars
represent mean ± SD of duplicate measurements. (B) FACS analysis of intracellular FOXP3 staining. (C) Analysis of cell lysates from equal numbers
of Jurkat cells followed by FOXP3-specific Western blot analysis. All data are representative of at least two independent experiments.
Figure 2 IL-2 expression in resting and PMA/ionomycin–stimulated Jurkat cell lines. (A) Quantitative real-time RT-PCR for IL-2 expression.
Bars represent mean ± SD of duplicate measurements. (B) FACS analysis of intracellular IL-2 staining. All data are representative of at least two
independent experiments.
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overall size of the chromosome (Pearson correlation coef-
ficient rresting = 0.91 with p = 7.07 × 10
-10 and rstimulated =
0.96 with p = 2.12 × 10-13; data not shown). A table of the
identified FOXP3 ChIP regions and a visualized genomic
map can be found in Additional File 1.
FOXP3 preferentially binds in intronic regions located
+1.6 kb from TSS
To deduce biological meaning and more universal
genome-wide characteristics of FOXP3 binding, we had
to link the identified ChIP regions to known genome
annotations and thus to potential FOXP3 target genes.
To this end, we first used the Cis-regulatory Element
Annotation System (CEAS) [17] to describe the posi-
tions of the ChIP regions in terms of known genomic
feature annotation. Figure 3A gives a summary of the
annotation categories provided by the CEAS database.
According to the annotation, in both resting and stimu-
lated J-FOXP3 T cells more than 50% of annotated ChIP
regions are located between the transcription start site
(TSS) and -10 kb. This finding was not unexpected, con-
sidering the fact that this range reflects most of the en-
tire promoter coverage area interrogated by the tiling
microarray. However, nearly 40% of annotated ChIP
regions are located within an intron and thus areFigure 3 Positional annotation of FOXP3 ChIP regions. (A) CEAS annot
feature categories within the promoter coverage range of the tiling microa
and randomly generated ChIP regions to their closest TSS as determined w
the tiling microarray used. Bandwidth of the histograms is 172 bp.situated within the comparably small range from TSS to
+2.45 kb. The remaining ChIP regions (~10%) fall into
the positional categories: 50 untranslated region (UTR),
Exon, 30 UTR and immediate downstream. Taken to-
gether, the findings of the CEAS annotation show that
FOXP3 binds preferentially to intronic regions, inde-
pendent of mitogenic stimulation.
To analyze the positional distribution of FOXP3 TFBS
in reference to the TSS in more detail, we annotated the
identified ChIP regions with the Genomic Position An-
notation Tool (GPAT) [18]. GPAT was used in the pro-
moter search mode, and annotation results were
restricted to the tiling array’s promoter coverage range
(-10 kb to +2.45 kb around the TSS). GPAT annotation
resulted in 1998 annotated ChIP regions referencing
2011 gene entities in resting J-FOXP3 T cells and in
2127 ChIP regions referencing 2024 gene entities in sti-
mulated J-FOXP3 T cells. The distances from all anno-
tated ChIP regions to the closest TSS are presented in a
histogram (Figure 3B). Interestingly, the positional distri-
bution of ChIP regions downstream of TSS shows a
marked peak at an average distance of about +1.6 kb
from TSS. This main peak can be considered to result
from FOXP3-bound intronic ChIP regions. However, the
ChIP region distribution appears similar in both resting
and stimulated conditions. A random compilation ofation showing the frequency of ChIP regions in common genomic
rray. (B) Frequency of distances (in kb) of experimentally determined
ith the GPAT tool within the minimum promoter coverage range of
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frequency distribution was further analyzed and under-
lined the meaning of the experiment-driven output of
genomic positions for FOXP3 binding.
Pathway analysis of gene entities that were derived by
GPAT annotation and that represented potential direct
FOXP3 target genes was performed with GeneGO soft-
ware (Thomson Reuters, New York, USA, see Additional
File 2). Especially under resting conditions, the analysis
identified significant (p < 0.05) enrichment of genes
involved in pathways for co-stimulation of T cells, such
as the CD28, CD40, ICOS, and CTLA-4 signalling path-
ways. Genes involved in pathways with general import-
ance for T-cell activation, such as the NFAT, AKT,
calcium and cAMP signaling pathways, were also overre-
presented (p < 0.05). Of note, the IL-17 signalling path-
way also appeared to be affected (p < 0.05) in the
presence of FOXP3 protein.
FOXP3 binding to certain promoter regions is associated
with transcriptional changes
To link the potential competence of identified ChIP
regions to FOXP3-dependent expressional changes in
Jurkat T cells, we performed whole-genome expression
analyses and then determined the association between
expression data and promoter occupation data derived
from the ChIP-on-chip studies. Expression analysis was
performed on resting and PMA/ionomycin–stimulated
J-GFP and J-FOXP3 T cells. Finally, we applied an ana-
lysis strategy (as described in Materials and Methods) to
compile a list of 410 transcripts that exhibited FOXP3-
dependent transcriptional changes. Expression data from
these 410 transcripts were hierarchically clustered,
resulting in 8 gene clusters. The complete set of micro-
array expression data is provided in Additional File 3.
We combined the expression data with the GPAT ChIP
region annotation list to determine the association be-
tween observed expressional changes and the binding or
absence of binding of FOXP3 to the promoter region of
a certain transcript. Figure 4 shows the hierarchical clus-
tering of the 410 regulated transcripts and also indicates
whether and in which experimental condition the asso-
ciated gene was found in the ChIP region annotation list.
Of the 410 regulated transcripts, 90 were associated with
at least one ChIP hit in at least one of the two experi-
mental conditions.
IL-22 is a direct transcriptional target of human FOXP3
transcription factor activity
In stimulated J-FOXP3 vs. J-GFP T cells, the cytokines
TGF-β2 (-3.8), IL-26 (-4.0) and IL-22 (-3.8) were among
the most down-regulated genes. Their FOXP3-dependent
repression after treatment with PMA/ionomycin was con-
firmed by real-time RT-PCR (Figure 5). Interestingly, asshown in Figure 4, the observed down-regulation of IL-22
in stimulated J-FOXP3 T cells was accompanied by FOXP3
binding only under stimulated conditions. Thus, we
hypothesized that IL-22 might be a stimulation-dependent
direct target gene of FOXP3. Interestingly, the IL-22 gen-
omic locus is part of a small gene cluster comprising IFN-γ,
IL-26, and IL-22. The IL-22 gene lies on the minus strand
of the human genome and encodes for 5 exons. Figure 6A
shows the local genomic situation at the IL-22 locus in
more detail.
Interestingly, a reproducible FOXP3 binding site can
be found in proximity (3646 bp) to the IL-22 TSS, a
finding suggesting that this site is responsible for the
observed stimulation-dependent repression of IL-22 ex-
pression in PMA/ionomycin treated J-FOXP3 T cells. A
prerequisite for a direct FOXP3 target gene is the occur-
rence of at least one FOXP3 binding site in the gene’s
promoter region. Hence, under this aspect we analyzed
the corresponding IL-22 promoter ChIP region (region
ID: chr12.119, see Additional File 1) with a length of
36 bp. Figure 6B shows the DNA sequence of the IL-22
ChIP region on chromosome 12 and the corresponding
FOXP3 FKH consensus sequence [8]. Strikingly, in the
middle of the ChIP region there was a perfectly match-
ing FOXP3 consensus site with the following genomic
coordinates: chr12 66937190 – 66937197 (hg18 refer-
ence assembly). Genomic site-specific real-time PCR of
this binding region confirmed about 5-fold ChIP enrich-
ment (Figure 6C).
To ultimately check whether FOXP3-dependent sup-
pression of IL-22 following PMA/ionomycin treatment
occurs in primary ex vivo isolated FOXP3+ T cells as well,
CD4+CD25+FOXP3+ Treg cells and naïve CD4+CD25-
FOXP3- T cells were isolated from healthy donors using
MACS technology. Following 4 h of PMA/ionomycin
stimulation the cells were analyzed for FOXP3 and IL-22
expression in comparison to resting cells using real-time
PCR (Figure 7). As expected, the fold induction of IL-22
expression was significantly reduced (p < 0.05) in FOXP3+
Treg cells compared to conventional naïve FOXP3- T
cells.
Discussion
We chose to identify the functional genomic sites of dir-
ect DNA occupation by FOXP3Δ2 protein by using a
combination of matching ChIP-on-chip and expression
microarray data from human FOXP3-expressing Jurkat
T cells under resting and stimulated conditions. Mito-
genic stimulation with PMA and ionomycin ensures a
strong simultaneous and swift T-cell activation circum-
venting the upstream T-cell receptor signaling, thereby
allowing efficient triggering of its downstream signaling
events, including activation of protein kinase C and trig-
gering of Ca2+ influx, both of which are known to
Figure 4 (See legend on next page.)
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Figure 4 Cluster analysis of FOXP3-dependent expressional changes in resting and PMA/ionomycin–stimulated J-FOXP3 and J-GFP
cells. Color coding represents z-scores of normalized expression signal intensities. Black boxes indicate the presence of at least one FOXP3 ChIP
region within the transcript’s promoter region in the range of -10 kb to +2.45 kb around the TSS as determined by ChIP-on-chip analysis and
GPAT annotation of resting and stimulated J-FOXP3 cells.
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our dataset allows us to distinguish FOXP3 binding and
reversal of binding under resting conditions from altera-
tions in FOXP3 binding behavior under stimulated con-
ditions and to determine the direct impact on
transcriptional alterations under the very same circum-
stances. Since in previous human FOXP3 ChIP studies
by Sadlon and colleagues [7] and Bierzele and colleagues
[20] only ChIP DNA from stimulated cell material has
been analyzed, our dataset provides deeper insights into
condition-dependent FOXP3 interaction with genomic
DNA.
The tiling microarray we used interrogates proximal
promoter regions of genes (basically -7.5 kb to +2.45 kb
around the TSS), thereby defining comparatively narrow
genomic regions predominantly with potential compe-
tence for direct transcriptional regulation of adjacent
gene loci. We identified 3343 ChIP hits with proximity
to 2011 GPAT-annotated gene entities under restingFigure 5 Validation of FOXP3-dependent gene repression.
Expression of IL-22, IL-26 and TGF-β2 in resting and PMA/ionomycin-
stimulated J-FOXP3 T cells by quantitative real-time RT PCR. Bars
represent mean ± SD of duplicate measurements and are
representative for two independent experiments..conditions and 3632 ChIP hits with proximity to 2024
GPAT-annotated gene entities under stimulated condi-
tions. Of 410 markedly FOXP3-dependent transcripts, as
defined by the expression microarray analysis, 90 (22%)
were associated with at least one ChIP hit within the
promoter coverage range of the tiling microarray. The
discrepancy between the much higher number of gene
entities with nearby FOXP3 ChIP hits within their pro-
moter regions as opposed to the number of transcripts
that are in fact transcriptionally altered has been
observed in previous murine and human FOXP3 ChIP-
on-chip studies as well [7, 20–22]. This finding stresses
the apparent presence of numerous silent or ineffective
yet specific FOXP3 binding events in proximal promo-
ters. However, about the biological meaning of such si-
lent binding events can be speculated, but may for
instance be explained in part by the interaction of
FOXP3 with other transcription factors that may attenu-
ate or block its functional influence on the transcription
of an adjacent gene.
To compare our annotated ChIP data to those from
previous human FOXP3 ChIP studies by Sadlon [7] and
Bierzele [20], which similarly provide lists of experimen-
tally identified FOXP3 target genes, we matched all
annotations to 33024 known and approved unambiguous
gene symbols provided by the HUGO Gene Nomencla-
ture Committee (HGNC) [23]. Our data represent 1905
entries in resting J-FOXP3 cells, 1915 entries in stimu-
lated J-FOXP3 cells and 3429 combined HGNC entries
(see Additional File 4). Data from Sadlon et al. resulted
in a set of 4040 HGNC gene symbols, and data from Bir-
zele et al. resulted in a set of 5247 HGNC gene symbols.
Combined, both sets represent 7845 unambiguous gene
symbols. Consistently, 41% (1425; p = 1.19 × 10-132) of
the gene symbols in our dataset are also present in the
combined Sadlon/Birzele gene table. Combining all four
datasets separately resulted in an significant overlap of
48 loci (p = 2.25 × 10-202) that have been consistently
identified as targets for FOXP3 binding (Figure 8). Given
all technical variances that had an impact on the four
datasets, e.g., the source of the cell material (in vitro
expanded Tregs, ex vivo isolated Tregs, or Jurkat T cells
overexpressing FOXP3) and the type of cell treatment
(α-CD3/α-CD28 antibody, ionomycin, PMA/ionomycin
treatment, or no treatment) and its duration (16 h, 4 h
or 2 h), it is likely that these 48 genes are highly import-
ant for determining the basic Treg cell phenotype and
function and are predominant targets of FOXP3 under
Figure 6 IL-22 gene locus on chromosome 12 in more detail. Generated ChIP-on-Chip data within the tiling array’s coverage range of the
IL22 promoter alongside with RefSeq annotation. (A) ChIP peaks represent -10 x log10 of p-values derived from the local comparison of probe
signal intensities from tiling microarrays of FOXP3-specific and isotype control IPs from two independent experiments using resting and PMA/
ionomycin–stimulated J-FOXP3 cells. Positional overlap of ChIP regions above the p-value threshold (95th percentile) in the two replicate ChIP
experiments is summarized in red below. (B) Sequence of summarized ChIP region chr12.119 identified in A and aligned with FOXP3 consensus
sequence [8]. Chromosomal coordinates refer to hg18 genomic reference assembly. (C) Fold enrichment of ChIP region chr12.119 in FOXP3-
precipitated J-FOXP3 material as determined by genomic quantitative real-time PCR.
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genes there are prominent ones such as CTLA4, NFAT5,
NFKB1, RUNX1, and TNFSF10, all of which have previ-
ously been substantially associated with Treg phenotype,
FOXP3 interaction, or both [24–30].
Both the FOXP3Δ2 isoform and the FOXP3Δ7 isoform
can inhibit T-cell activation [31] and contribute to the
phenotype of human nTregs [32, 33]. However, FOXP3
exon 2, which encodes for a portion of the FOXP3
repressor domain, has been specifically shown to be es-
sential for interaction with and repression of retinoic
acid–related orphan receptors α and γt (RORα, RORγt)
[34, 35]. Both the RORα and the RORγt TFs are in turn
essential for Th17 commitment of T cells [36–38]. Thus,
FOXP3 expression is considered a key element prevent-
ing the establishment of a full Th17 phenotype in T cells
[35].
However, in the context of T-cell plasticity some
reports indicate that human RORγt+FOXP3+ Tregs ex-
hibit the characteristics of both Tregs and Th17 cells.
Consistently, it has been shown that isolated IL-17 pro-
ducing FOXP3+ T cells that express RORγt sharefeatures of conventional RORγt+ Th17 cells. Interest-
ingly, RORγt+FOXP3+ Tregs cannot sufficiently produce
IL-22 after PMA/ionomycin stimulation [39]. Because
we found that the presence of FOXP3 (even if exon 2 is
missing) is sufficient to suppress the expression of the
Th17-related cytokines IL-26 and, especially, IL-22, it is
reasonable to speculate that the identified FOXP3 TFBS
in the IL-22 promoter explains the inability of RORγt+
FOXP3+ T cells to produce IL-22 on the transcriptional
level.
Conclusions
We successfully applied a combination of the state-of-
the-art ChIP-on-chip analysis and expression microarray
analysis to identify direct transcriptional targets of the
human TF FOXP3Δ2 expressed in Jurkat T cells under
resting and mitogen-stimulated conditions. Our results
demonstrate that FOXP3 prefers intronic regions, inde-
pendent of the cellular activation status. Notably, we
found that genes important for the co-stimulation of T
cells are transcriptional targets of FOXP3. In particular,
we identified the Th17 lineage-related cytokine IL-22 as
Figure 7 Expression of FOXP3 and IL-22 in ex vivo isolated
human T cells. Human CD4+CD25- (Tnaiv) and CD4
+CD25+ (Treg)
cells were isolated from healthy donors (n = 6-8) using AutoMACS
technology and were either stimulated with PMA and ionomycin for
4 h or left untreated. Cells were subsequently analyzed by
quantitative real-time RT-PCR (A) Expression of FOXP3 normalized to
median expression of resting Tnaiv. (B) Fold induction of IL-22
comparing stimulated vs. resting cells. The median and individual
measurements are shown. Asterisk indicates p < 0.05 in a two-sided
Mann-Whitney U test.
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These results complete the picture of FOXP3 as a tran-




The FOXP3Δ2-expressing retrovirus (pRV-FOXP3Δ2-
IRES-GFP) and the empty control virus (pRV-IRES-
GFP) were generated as previously described [40, 41].
Briefly, the following primer pair was used to amplify
the FOXP3Δ2 coding sequence from cDNA derived from
human CD4+ T cells: 50-cgggatccGGACAAGGACCC
GATGCCCAACC-30, 50-CCCTGCCCCCACCACCTCT
GC-30. Retroviruses were transfected into PT67 pack-
aging cell lines by calcium phosphate precipitation. Virus
particles were produced by cultivating transfected PT67
cells for 24 h at 37°C in Iscove’s Modified Dulbecco’s
Medium (IMDM) supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 100 U/ml penicil-
lin/streptomycin. Remaining packaging cells were
removed by filtering culture supernatants through a 0.2-
μm syringe filter, after which 3 to 4 × 106 Jurkat T cells
were resuspended in 2.5 ml of virus supernatant in a 6-
well culture plate. Next, 2.5 μl polybrene (8 mg/ml
Sigma-Aldrich, Steinheim, Germany) and 50 μl HEPES
(Invitrogen, Darmstadt, Germany) were added per well.
Cells were centrifuged at room temperature at 500 × g
for 2 h and were further incubated for 24 h at 37°C.Transduction efficiency was checked by flow cytometry,
and GFPhigh T cells were sorted with a BD FACSAria II
cell sorter (Becton Dickinson [BD], Franklin Lakes, New
Jersey, USA), followed by further cell expansion in
IMDM.
Isolation of primary human T cells
CD4+CD25+FOXP3+ and naïve CD4+CD25+FOXP3- T
cells were isolated from leukapheresis filters which were
kindly provided by the Institute for Transfusion Medicine
and Immune Hematology of the University Hospital Mag-
deburg. Cells were isolated using human CD4+CD25+
Regulatory T Cell Isolation Kit and AutoMACS device
(both Miltenyi Biotec, Bergisch Gladbach, Germany)
according to manufacturer’s instructions. Purity of isolated
cells was checked by flow cytometry using CD3-FITC
(clone OKT3, eBioscience, San Diego, CA, USA), CD4-
PE-Cy7 (clone RPA-T4, eBioscience, San Diego, CA, USA)
and CD25-PE (clone 4E3, Miltenyi Biotec, Bergisch Glad-
bach, Germany) antibody.
RNA isolation
RNA was isolated by using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
recommendations. DNA was digested by using the
RNase-Free DNase Set (Qiagen). RNA was eluted in
100 μl nuclease-free water and further concentrated by
ethanol precipitation, beginning with the addition of 2 μl
linear polyacrylamide (0.5 μg/μl,; Ambion, Darmstadt,
Germany), 50 μl 7.5 M NH4OAc (Sigma-Aldrich), and
375 μl absolute ethanol, precooled to -20°C. RNA was
precipitated for at least 2 h at -70°C and was then centri-
fuged at 14,000 × g at 4°C for 30 min in a table-top cen-
trifuge. The RNA pellet was washed twice with 80%
ethanol at -20°C, dried, and resuspended in nuclease-free
water. RNA integrity was tested by using the Agilent
2100 Bioanalyzer (Agilent Technologies, Böblingen,
Germany) with an Agilent RNA 6000 Nano/Pico Kit
(Agilent Technologies).
Real-time PCR
Equal amounts of RNA were used for cDNA synthesis in
a reverse transcription reaction using a mixture of 0.5 μl
oligo-dT (0.5 μg/μl) and 0.5 μl random primers (3 μg/μl)
and nuclease-free water (total volume, 12 μl). Samples
were incubated for 10 min at 70°C and then put on ice
for 10 min. Reverse transcription (RT) reaction mix was
added, containing 4 μl 5x first-strand buffer (Invitrogen),
2 μl dithiothreitol (DTT; 0.1 M, Invitrogen), 1 μl dNTP
Mix (10 mM, Invitrogen), and 1 μl SuperScript II Re-
verse Transcriptase (Invitrogen).
Samples were incubated for 60 min at 42°C in a ther-
mocycler. Real-time PCR was performed in duplicate
with LightCycler 480 SYBR Green I Master reaction mix
Figure 8 Comparison with previously published human FOXP3 ChIP studies. Venn diagram comparing numbers of experimentally identified
FOXP3 target genes from depicted human FOXP3 ChIP studies with our findings derived from resting and stimulated J-FOXP3 cells. For
comparison, all data were matched to unambiguous gene symbols from the HUGO Gene Nomenclature Committee.
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system (Roche). PCR reactions were performed with 1 μl
cDNA, 5 μl primer mix (containing forward and reverse
primer, 500 nmol/l each), 10 μl 2x concentrated Light-
Cycler 480 SYBR Green I Master mix (Roche), and 4 μl
nuclease-free water. Relative mRNA levels were deter-
mined by using standard curves for each gene, and
quantitative normalization of gene expression was per-
formed in relation to the expression of the housekeeping
gene RPS9. As a template for the standard curves, a mix-
ture of all samples in 4 serial dilutions was used, corre-
sponding to 3, 1, 0.1, and 0.01 μl template amount. The
following PCR temperature cycles were used (45 cycles
were performed): Step 1: 95°C, 5 min; Step 2: 95°C,
10 sec; Step 3: 55-60°C (primer dependent), 10 sec; Step
4: 72°C, 10 sec; Step 5: 4°C, hold. Real-time PCR data
were analyzed with LightCycler 480 software (Roche).
Confirmation of ChIP enrichment by site-specific gen-
omic real-time PCR was performed by using amplified
ChIP DNA from FOXP3-specific immunoprecipitation
and from isotype control immunoprecipitation and in
reference to an unrelated genomic region within the
RPS9 gene. The following primers were used: RPS9 for:
50-CGCAGGCGCAGACGGTGGAAGC-30, RPS9 rev: 50-
CGAAGGGTCTCCGCGGGGTCACAT-30, IL-2 for: 50-
GTCACAAACAGTGCACCTAC-30, IL-2 rev: 50-ATGG
TTGCTGTCTCATCAGC-30, FOXP3 for: 50-GAACGC
CATCCGCCACAACCTGA-30, FOXP3 rev: 50-CCCTGC
CCCCACCACCTCTGC-30, IL-22 for: 50-CAACAGGC
TAAGCACATGTCA-30, IL-22 rev: 50-ACTGTGTCCT
TCAGCTTTTGC-30, IL-26 for: 50-AGCAACGATTCCAGAAGACC-30, IL-26 rev: 50-TGCAGTTGACCAA
AAACGTC-30, TGF-β2 for: 50-CCAAAGGGTACAAT
GCCAAC-30, TGF-β2 rev: 50-CAGATGCTTCTGGATT
TATGGTATT-30, IL-22 chr12.119 for: 50-AAGCCCA
CCTCCCAGGTCCC-30, IL-22 chr12.119 rev: 50-AGAC
AGCCAAAGCCTACTTCTGGT-30Western blot
FOXP3 expression in transduced Jurkat T cells was
detected by Western blot analysis. FOXP3 was detected
by using monoclonal mouse anti-human FOXP3 anti-
body (clone 206D; Biolegend, San Diego, CA, USA;
1:1000 dilution in Tris buffered saline Tween 20 (TBS-
T) buffer with 5% milk powder). For detection, a second-
ary polyclonal goat anti-mouse antibody conjugated to
horseradish peroxidase (Dianova, Hamburg, Germany;
1:4000 in TBS-T buffer with 5% milk powder) was used.Intracellular cytokine staining
For intracellular cytokine detection, cells were cultured
in IMDM medium and re-stimulated with PMA (final
concentration, 10 ng/ml) and ionomycin (final concen-
tration, 1 μg/ml) for 4 h. For the final 2 h of incubation,
brefeldin A (Sigma-Aldrich) was added to block the se-
cretion of cytokines. Subsequently, cells were fixed with
1% (v/v) paraformaldehyde solution in phosphate-
buffered saline (PBS). Cells were permeabilized with
0.1% IGEPAL (Sigma-Aldrich) in PBS for 5 min. IL-2
staining was performed for 30 min (mouse anti-human
IL-2 APC, clone 5344.111; BD).
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Jurkat T cells were cultivated in IMDM medium supple-
mented with 10% FCS (PAA Laboratories) and 100 U/ml
penicillin/streptomycin. If stated, cells were stimulated
with PMA (10 ng/ml, Sigma-Aldrich) and ionomycin
(1 μg/ml, Sigma-Aldrich) for 4 h. Protein crosslinking
was ensured by the addition of formaldehyde (1% v/v)
and by incubation on a shaker for 10 min at room
temperature. Formaldehyde was quenched for 5 min by
the addition of glycine (125 mM final concentration).
After centrifugation, the culture supernatant was
removed, and cells were washed once with ice-cold PBS.
Cells were lysed in IP cell-lysis Buffer (10 mM Tris HCL
[pH 7.5], 10 mM NaCl, 3 mM MgCl2, 1 mM phenyl-
methanesulfonyl fluoride [PMSF] 0.5% v/v IGEPAL CA-
630) and incubated on ice for 10 min. Lysed cells were
centrifuged at 2500 rpm for 5 min at 4°C, and the super-
natant was discarded. The chromatin material was
obtained by lysing the cell nuclei with IP nuclei-lysis
buffer (50 mM Tris HCL [pH 8.0], 10 mM EDTA, 1%
[v/v] sodium dodecyl sulfate [SDS], complete protease
inhibitors) and incubating them on ice for 10 min. Chro-
matin was diluted in IP dilution buffer (20 mM Tris HCl
[pH 8], 2 mM EDTA, 1% v/v Triton X-100, 150 mM
NaCl, 1 mM PMSF) and stored at -80°C.
ChIP chromatin corresponding to 5 × 107 cells was
fragmented with a Branson Sonifier 250 (Branson Ultra-
sonics, Danbury, USA) equipped with a microtip. The
following sonication conditions were applied: 60% duty
cycle, maximum output power; 6 to 7 sonication cycles
consisting of 30 sec on and 60 sec off. Average DNA
fragment size was between 200 and 1000 bp. The IP
process was performed essentially as described by the
Affymetrix company: Protein G Sepharose 4B (Zymed,
San Francisco, USA) and either 10 μg anti-human
FOXP3 antibody (clone 206D, mouse IgG1,к; BioLegend)
or 10 μg of isotype control antibody (clone MOPC-21,
mouse IgG1,к; BioLegend) were used per IP, respectively.
After adapter ligation (adapter primer: 50-GTTTCC
CAGTCACGGTC(N)9-3
0), ChIP DNA was amplified
with a large-scale PCR reaction (amplification primer:
50-GTTTCCCAGTCACGGTC-30) involving Ampli Taq
Gold DNA polymerase and partial incorporation of
deoxyuridine triphosphate (dUTP). Amplified ChIP
DNA was labelled and prepared for hybridization with
the GeneChip WT Double-Stranded DNA Terminal La-
beling Kit (Affymetrix) and was then analysed on a
Human Promoter 1.0R tiling microarray (Affymetrix).
Tiling microarray data analysis
Basic tiling array data analysis was performed with TAS
software (Version 1.1.02, Affymetrix). FOXP3-bound
ChIP-enriched genomic regions were identified by com-
paring FOXP3 IP to a matched isotype control IP fromthe same cell material. Only continuous genomic regions
exhibiting a p-value higher than the 95th percentile of
all p-values were included in subsequent analyses. Both
resting and PMA/ionomycin–stimulated conditions were
analyzed in independent duplicate experiments. Each
replicate experiment was analyzed separately. Calculated
ChIP intervals were visualized with IGB software [42].
The web-based Galaxy analysis tool [43] was used to
compare repetitive ChIP-on-chip experiments. Positional
intersecting ChIP regions between two replicate experi-
ments were calculated; thus, these regions represented
genomic regions that were identified in both ChIP-on-
chip replicates. Moreover, the range of intersection was
calculated, and only the corresponding genomic coordi-
nates of intersecting areas were considered for further
analysis. The tiling microarray data discussed in this
publication have been deposited in NCBI's Gene Expres-
sion Omnibus [44, 45] and are accessible through GEO
Series accession number GSE37256 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE37256). Signifi-
cance of the overlap between different lists of HGNC
gene symbols was calculated using a hypergeometric
test.
Expression microarray analysis
Equal amounts of RNA were amplified with a double
linear amplification protocol, starting with the synthesis
of double-stranded cDNA by using the T7dT23 primer
(50-GGCCAGTGAATTGTAATACGACTCACTATAGG
GAGGCGG(T)23-3
0; Metabion, Planegg, Germany) and
SuperScript II reverse transcriptase (Invitrogen, Karlsruhe,
Germany). A second-strand cDNA synthesis was then
performed with DNA polymerase I (Invitrogen) and
E. coli DNA ligase (Invitrogen). After purification of
double-stranded cDNA, the first amplification round
was performed in an in vitro transcription reaction
by using the Promega P1300 RiboMax Kit for T7 amplifi-
cation (Promega, Mannheim, Germany); this procedure
produced unlabeled cRNA. The amplified cRNA was sub-
jected to a second amplification round, starting again with
reverse transcription by using random hexamer primers
(Pharmacia, Freiburg, Germany) for first-strand synthesis
of cDNA, followed by cRNA degradation with RNase
H treatment. T7dT23 primers were again used for the
second-strand synthesis, as described above. In the
second in vitro transcription, which used the GeneChip
expression 30-Amplification Reagent Kit for labeling
(Affymetrix, San Francisco, CA, USA), biotinylated
UTP was partially incorporated into the final cRNA.
The quantity and quality of biotinylated cRNA were
checked photometrically. Biotinylated cRNA was fragmen-
ted, hybridized to a Human Genome U133 Plus 2.0 Array
(Affymetrix), washed, and stained as recommended by the
manufacturer. Microarray data were analyzed with
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the Robust Multi-array Analysis (RMA) normalization al-
gorithm. Cluster analysis was performed with Genesis
Software 1.7.3 [46] by using a z-score transformation [47].
A list of 410 FOXP3-dependent genes was compiled by
combining two analysis strategies. First, J-FOXP3 cells
were compared with J-GFP cells. Genes were considered
to be influenced by the over-expressed FOXP3 protein
only if their expression showed at least a two-fold change
(up or down) under either stimulated or unstimulated
conditions. In a second strategy, stimulated and resting J-
FOXP3 and stimulated and resting J-GFP cells were com-
pared by calculating the differences in gene expression.
Only genes that showed at least a two-fold change in
stimulation-dependent induction or repression were con-
sidered to be influenced by the over-expressed protein.
Subsequently this list of stimulation-dependent transcripts
was filtered for differences between FOXP3-expressing
cells and GFP control cells. Only transcripts that exhibited
at least a two-fold difference in stimulation dependency
between J-FOXP3 and J-GFP cells were retained. Both
analysis strategies resulted in a combined list of 410
FOXP3-dependent genes. The expression microarray data
discussed in this publication have been deposited in NCBI's
Gene Expression Omnibus [44, 45] and are accessible
through GEO Series accession number GSE37256 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37256).
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